We spoke to @adamssperling (@DanaFarber), who shared some insights into the role of clonal hematopoiesis in multiple myeloma and other hematological malignancies: 🎥: http://ow.ly/GGiK50KVRjM #MMsm #HemOnc #BloodCancerAwarenessMonth #IMS2022
We had a great interview with Catherine Coombs of @UNC, who shared some insights into novel BTK inhibitors in CLL and future outlooks. @SocietyofHemOnc #SOHO22 #HemOnc #LeuSM #CLLsm
Great discussion today, thanks Jorge, see you in Mandelieu for ESH CML meeting https://twitter.com/vjhemonc/status/1575582501913100288
A great session we had here today at #SOHO22 with CML experts Jorge Cortes (@GCC_Cortes) & Mhairi Copland (@CoplandMhairi)! Stay tuned for more of our expert-led discussions! @SocietyofHemOnc #SOHO2022 #HemOnc #LeuSM #CMLsm
#SOHO22 | Peter Valk (@ErasmusMC) discusses TP53-mutated AML and MDS, the prognostic value of FLT3-ITD residual disease in AML, and more. Visit http://VJHemOnc.com for our interviews from this year's meeting! #SOHO2022 #HemOnc #LeuSM #AMLsm #MDSsm
At #SOHO22: Our Dr. Robert Orlowski discusses early data in bispecific T cell engagement for treatment of multiple myeloma. @Myeloma_Doc #EndCancer
EHA 2020 Top Picks
EHA 2020 saw the unveiling of a whole host of practice-changing updates. View our in-depth feature article detailing our top picks!
CAR-T & Cellular therapy at EHA
Find out about the latest CAR T-cell therapies, toxicity and management data, role in transplant, and the future of the field.
Explore the latest updates in MRD by disease type, including expert interviews from EHA 2020, podcasts and e-learning
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest hemonc news and updates
Keep up to date with all the latest news with our monthly newsletter